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Muscle Cells
Gang Xi, Xinchun Shen, Laura A. Maile, Christine Wai, Katherine Gollahon, and David R. Clemmons
IGF-I–stimulated sarcoma viral oncogene (Src) activation during
hyperglycemia is required for propagating downstream signaling.
The aim of the current study was to determine the mechanism by
which hyperglycemia enhances IGF-I–stimulated Src activation
and the role of NADPH oxidase 4 (Nox4) and protein kinase C
z (PKCz) in mediating this response in vascular smooth muscle
cells (VSMCs). Nox4 expression was analyzed in VSMCs exposed
to hyperglycemia. The role of Nox4-derived reactive oxygen spe-
cies (ROS) in IGF-I–stimulated Src activation was investigated via
knockdown of Nox4. Different isoforms of PKC were screened to
investigate their role in hyperglycemia-induced Nox4. The oxida-
tion of Src was shown to be a prerequisite for its activation in
response to IGF-I during hyperglycemia. Hyperglycemia induced
Nox4, but not Nox1, and p22 phagocyte oxidase (p22phox) expres-
sion and IGF-I stimulated Nox4/p22phox complex formation, lead-
ing to increased ROS generation. Knockdown of Nox4 prevented
ROS generation and impaired the oxidation and activation of Src in
response to IGF-I, whereas knockdown of Nox1 had no effect.
PKCz was shown to mediate the hyperglycemia-induced increase
in Nox4 expression. The key observations in cultured VSMCs were
confirmed in the diabetic mice. Nox4-derived ROS is responsible
for the enhancing effect of hyperglycemia on IGF-I–stimulated Src
activation, which in turn amplifies IGF-I–linked downstream sig-
naling and biological actions. Diabetes 61:104–113, 2012
H
yperglycemia is a risk factor for diabetes compli-
cations (1). Inhibition of hyperglycemia-induced
reactive oxygen species (ROS) generation at-
tenuates these changes (2). In vascular smooth
muscle cells (VSMCs), hyperglycemia enhances the cel-
lular responsiveness to IGF-I, including increased cell
proliferation and migration (3), processes that contribute
to atherosclerosis (4). VSMCs adapt to hyperglycemia by
changing the signaling components that respond to IGF-I
stimulation (5). The induction of sarcoma viral oncogene
(Src) kinase is one of these changes (6,7), and activated Src
has been linked to diabetic vascular complications (8).
The Src kinase domain is maintained in an inactive state
by intramolecular interactions (9,10) and activated by
disruption of these interactions with high-affinity ligands
(11,12). Changing Src oxidation has been proposed as an
important factor for regulating Src activation (13,14). Src
undergoes activation after oxidation of Cys245 and Cys487
during focal adhesion formation (15), and exposure of
platelets to hydrogen peroxide induces Src activation (16).
ROS are generated in a variety of conditions that are as-
sociated with increased cell proliferation/migration (17). In
vascular cells, NADPH oxidase (Nox) is a major source for
intracellular ROS generation (18). Nox4 is one of the major
isoforms in vascular cells (19), and Nox4-derived ROS has
been shown to be required for Src activation in response to
angiotensin-II (14). However, the mechanism by which the
Nox4-mediated increase in ROS leads to Src activation was
not determined.
In VSMCs, Nox4 has been shown to be associated with
an IGF-I–stimulated increase in ROS generation (20). Ad-
ditionally, high glucose has been shown to increase Nox4
expression in mesangial (21) and endothelial cells (22) in a
protein kinase C (PKC)–dependent manner. Therefore, we
investigated the relative roles of high glucose and IGF-I in
the induction of Nox4 activation and ROS generation, and
determined which PKC isoform mediates these changes.
Furthermore, we determined the mechanism by which hy-
perglycemia enhances IGF-I–stimulated Src oxidation and
kinase activation and verified the importance of these
changes in blood vessels of diabetic mice.
RESEARCH DESIGN AND METHODS
Human IGF-I was a gift from Genentech (South San Francisco, CA). The anti-
Src and 2, 4-dinitrophenyl antibodies were purchased from Millipore Corp.
(Billerica, MA). Dulbecco’s modified Eagle’s medium (DMEM) containing 25
mmol/L glucose, and 5 mmol/L glucose, streptomycin, penicillin, 29, 79-dichlor-
ofluorescein diacetate, and the Amplex red hydrogen peroxide assay kit were
purchased from Invitrogen (Carlsbad, CA). PD98059, protein kinase B (AKT)
inhibitor, BAY 11-7082, Gö 6976, PKC´ inhibitor, and the PKCz pseudosubstrate
inhibitor were obtained from EMD Bioscience (San Diego, CA). The anti-Src
homology collagen (Shc) antibody was purchased from BD Bioscience (San
Diego, CA). Antibodies against phospho-AKT (Ser 473), total AKT, pSrc (Tyr 419),
pErk1/2 (Thr202/Tyr204), and Erk1/2 (extracellular signal–related kinase 1/2) were
from Cell Signaling Technology, Inc. (Beverly, MA). Anti–p22 phagocyte oxidase
(p22phox), PY99, b-actin, PKCz, and IGF-I receptor antibodies were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-Nox1, Nox4, and Ki67
antibodies were purchased from Abcam (Cambridge, MA). All other reagents were
obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
Construction of cDNAs and establishment of Nox4 silenced (Si), PKCz
Si, Nox1 Si, and b-D-galactosidase (LacZ) Si cells. Based on the Invitrogen
website design tools, the oligonucleotides GGTGTATCCGGAGCAATAAAC,
GCCAGTGCAGCGAAAGGATAT, GGACAACCTGGCACTATTTG, and GCTA-
CACAAATCAGCGATTTwere used to construct the short hairpin RNA (shRNA)
template plasmids to knock down Nox4, PKCz, Nox1, and LacZ, respectively.
Plasmid construction, viral stock preparation, and transfection of VSMCs
expressing the corresponding shRNAs followed procedures described pre-
viously (23).
Immunoprecipitation and immunoblotting. The cell monolayers were lysed
in a modified radioimmunoprecipitation assay buffer (24). Immunoprecipita-
tion was performed by incubating 0.5 mg cell lysate protein (determined by
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bicinchoninic acid assay (BCA) according to the manufacturer’s instructions;
Thermo Fisher Scientific , [Rockford, IL]) with 1 mg of corresponding antibody
at 4°C overnight. Immunoblotting was performed as described previously (24).
Measurement of intracellular ROS level. Intracellular ROS was measured
using the DFC-DA assay as described previously (24). ForN-acetyl-cysteine (NAC)
treatment, 2 mmol/L NAC was added 18–20 h before IGF-I exposure or ROS
measurement. Diphenyleneiodonium (DPI; 10 nmol/L) was added 1 h before IGF-I
exposure or ROS measurement. Intracellular hydrogen peroxide was measured
using an Amplex red assay according to the manufacturer’s instructions.
Measurement of protein oxidation level. Protein oxidation was measured
using a modified OxyBlot protein detection kit (Millipore). After the immu-
noprecipitation of Src, the protein was released from the protein A beads using
12% SDS. Protein (10 mg) was derivatized with 20 ml 13 dinitrophenylhy-
drazine at room temperature for 15 min. The reaction was stopped by adding
15 ml neutralization solution and separated by a 7.5% polyacrylamide gel.
In vitro Src kinase assay. Src kinase activity was determined in vitro using a Src
kinase assay kit (Millipore) according to a procedure described previously (23).
Animal preparations and treatments. Animal maintenance conformed to
the U.S. National Institutes of Health Guide for the Care and Use of Laboratory
Animals. Hyperglycemia was induced in C57/B6 mice (Taconic, Hudson, NY)
using streptozotocin as described previously (25). Mice that had serum glu-
cose concentrations .250 mg/dL were considered diabetic. After induction
of diabetes, they were maintained for 2 weeks before any treatment. Based
on a published report (26), the animals received the PKCz inhibitor (n = 12)
(2 mg/kg i.p.) administered daily for 2 days before being killed. IGF-I (1 mg/kg i.p.
(n = 18) was administered 24 h for Ki67 staining and 15 min before being killed
for assessment of the signal transduction. The mice were fasted overnight (16 h)
before being killed.
Preparation of aortas for analysis. The mice were killed by injection of
Nembutal (100 mg/kg i.p.) before harvesting the aortas. The thoracic aortas were
harvested and placed into ice-cold PBS. Connective tissue and endothelium were
removed before protein extraction or fixation. For biochemical analyses, the aortas
were homogenized in ice-cold buffer (20mmol/L Tris, 150mmol/L sodium chloride,
2 mmol/L EDTA, and 0.05% Triton X-100, pH 7.4) using a glass tissue grinder.
Immunohistochemistry. The aortas from mice were fixed with 4% para-
formaldehyde overnight, and paraffin embedded sections were prepared by the
University of North Carolina Histology Core Facility. Antigen retrieval from the
paraffin-embedded sections was performed using Tris/EDTA buffer (pH 9.0) and
a programmed decloaking chamber (Biocare Medical, Concord, CA) before in-
cubation with an anti-Ki67 antibody (3 mg/mL). This was followed by incubating
with a biotin-conjugated goat anti-rabbit secondary antibody (1:2,000) and
horseradish peroxidase–conjugated avidin (1:4,000), respectively. Staining was
visualized using a DAB detection kit (Abcam). The Ki67-positive area in a whole
aortic ring was quantified using NIH ImageJ and expressed as the percentage of
the total area.
Cell proliferation assay. Assessment of VSMC proliferation was performed
as described previously (27). For NAC treatment, NAC (2 mmol/L) was added
for 18–20 h before IGF-I was added, and this was repeated after 24 h.
Cell migration assay. Cell migration assays were performed as described
previously (28).
Statistical analysis. The Student t test was used to compare differences
between control and one treatment or control cells and one mutant for most in
vitro experiments. One or two-way ANOVA was applied for all data obtained
from in vivo studies or when multiple treatments or multiple cell types were
compared using data from in vitro studies. P # 0.05 was considered statisti-
cally significant.
RESULTS
Oxidation of Src is required for IGF-I–stimulated Src
kinase activation. Hyperglycemia increased Src oxida-
tion in VSMCs (192 6 54% increase; P , 0.01) (Fig. 1A).
IGF-I induced a further 646 18% increase (P, 0.01). IGF-I
had a minimal effect in VSMCs maintained in 5 mmol/L glu-
cose. The antioxidant NAC prevented the IGF-I–induced
increase in Src oxidation (Fig. 1B). IGF-I stimulated an
89 6 19% increase (P , 0.01) in Src Y419 phosphoryla-
tion in high glucose but there was no significant change
in cells maintained in normal glucose (Fig. 1C). Hyper-
glycemia alone did not increase Src activation signifi-
cantly. Preincubation with NAC prevented the response
to IGF-I plus hyperglycemia (Fig. 1D), but it had no effect
on IGF-I receptor activation (Supplementary Fig. 1A). High
glucose alone did not increase Src kinase activity (Fig. 1E)
but H2O2 addition to cells cultured in normal glucose
increased Src kinase (e.g., 22 6 4% increase; P , 0.05).
IGF-I significantly increased Src kinase activity in cells
exposed to hyperglycemia (e.g., 186 6 12 vs. 45 6 8% in
normal glucose; P , 0.01) and this was inhibited by NAC
(e.g., 60 6 3%; P , 0.01) (Fig. 1E). Similarly, when IGF-I
was added with H2O2 to cells maintained in normal glucose,
it stimulated a 120 6 6% increase (P , 0.001) (Fig. 1E).
FIG. 1. Oxidation of Src is required for Src activation in response to
IGF-I. VSMCs were isolated from porcine aortas using a method that
has been described previously (50), cultured in DMEM containing
normal glucose (NG; 5 mmol/L) plus 10% FBS (Hyclone, Logan, UT),
and serum deprived for 16 h before treatment with 25 mmol/L glucose
(NHG) for 24 h or maintained in NG in the presence or absence of IGF-I
(100 ng/mL) for 1 min (A–E). For NAC treatment, 2 mmol/L NAC was
preincubated for 1 h before adding glucose (B, D, and E). For H2O2
treatment, 200 mmol/L H2O2 was preincubated for 1 h before IGF-I
exposure (E). A and B: Src was immunoprecipitated with an anti-Src
antibody. Oxidized Src levels were measured according to the pro-
cedure described in RESEARCH DESIGN AND METHODS. To control for loading,
the blots were stripped and probed with an anti-Src antibody (1:1,000
dilution). The proteins were visualized using enhanced chemilumines-
cence (Thermo Fisher Scientific). C and D: Cell lysates were immuno-
blotted with an anti-p419Src antibody (1:1,000). To control for loading,
the blots were stripped and probed with an anti-Src antibody. E: Src
protein was immunoprecipitated with an anti-Src antibody, and the im-
mune complexes were used to measure in vitro Src kinase activity ac-
cording to the procedure described in RESEARCH DESIGN AND METHODS. To
control for Src protein input, after immunoprecipitation, the same
amount of immune complexes from all treatments was immunoblotted
with an anti-Src antibody. *P < 0.05, **P < 0.01, and ***P < 0.001 in-
dicate significant differences between two treatments. The figures are
representative of three independent experiments except C and D,
which are representative of four.
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ROS is required for Src oxidation and activation in
response to IGF-I during hyperglycemia. ROS genera-
tion was significantly increased in 15 mmol/L glucose, and
25 mmol/L glucose induced greater increases (e.g., 279 6
20% increase, P , 0.01, compared with 5 mmol/L glucose)
(Fig. 2A). Mannitol had no effect. IGF-I stimulated an ad-
ditional 73 6 5% increase in ROS in cells exposed to 25
mmol/L glucose (P , 0.01), whereas its effect was minimal
in normal glucose (Fig. 2B). NAC prevented this increase
(Fig. 2C). Similar results were obtained using Amplex red
(Supplementary Fig. 1B and C). When H2O2 was added to
cells maintained in normal glucose, IGF-I–stimulated Src
activation reached a level that was similar to the cells main-
tained in high glucose (Fig. 2D). The response to IGF-I
plus H2O2 was prevented by NAC. H2O2 treatment also
increased basal Src activation (e.g., 39 6 13% increase; P ,
0.05) (Fig. 2D).
High glucose induces Nox4 and p22phox expression,
and IGF-I stimulates Nox4/p22phox complex formation.
To examine whether the increase in ROS in response to
IGF-I was due to Nox activation, DPI, a general Nox
inhibitor, was used. DPI significantly inhibited ROS
generation in response to high glucose (Supplementary
Fig. 2A and B). DPI also prevented Src activation in
response to IGF-I during hyperglycemia (Supplemen-
tary Fig. 2C and D).
Prior studies have shown that Nox1 and Nox4 are the
predominant forms of Nox expressed in VSMCs (29,30).
When VSMCs maintained in 5 mmol/L glucose were ex-
posed to 25 mmol/L glucose, Nox4 expression increased
after 6 h and reached a peak at 24 h (250 6 30% increase;
P , 0.05) (Supplementary Fig. 3A), whereas Nox1 increased
only 70 6 9% (Supplementary Fig. 3B). Increasing con-
centrations of glucose induced progressive increases in
Nox4 expression (Fig. 3A). A similar pattern was observed
in the expression of p22phox, which forms a complex with
Nox4 to generate ROS. Because a short (e.g., 10 min) ex-
posure to IGF-I had no effect on Nox4 expression (data
not shown) but it enhanced ROS generation, we deter-
mined whether IGF-I could stimulate Nox4/p22phox com-
plex formation. Nox4/p22phox complex formation was
increased after 1 min of IGF-I stimulation in high glucose
(Fig. 3B). To determine if hyperglycemia was required, we
cultured the cells in normal glucose and then switched to
high glucose for 24 h before IGF-I stimulation. This treat-
ment enabled IGF-I to enhance Nox4/p22phox complex
formation (e.g., a 184 6 34% increase after 1 min; P ,
0.001), whereas it had no effect at 1 min and it stimulated
FIG. 2. Hyperglycemia- and IGF-I–induced ROS are required for Src activation in response to IGF-I during hyperglycemia. A: VSMCs were cultured
in DMEM containing normal glucose (NG; 5 mmol/L) and serum starved for 16 h before addition of the indicated glucose concentration. Mannitol (25
mmol/L) was used as an osmotic control. B: VSMCs were cultured in DMEM containing high glucose (HG; 25 mmol/L) or NG (5 mmol/L) and serum
starved for 16 h before addition of IGF-I (100 ng/mL) for the indicated times. C: Cells were cultured in DMEM containing NG plus 10% FBS and serum
deprived for 16 h with DMEM containing NG or HG (NHG) before ROS measurement. NAC was added with serum-free DMEM and incubated for 16
h. ROS generation was determined according to the procedure described in RESEARCH DESIGN AND METHODS. D: Cells were cultured in DMEM containing
NG plus 10% FBS and serum deprived for 16 h in DMEM containing NG or HG (NHG). For NAC treatment, 2 mmol/L NAC was added and incubated
for 16 h before IGF-I treatment. H2O2 (200 mmol/L) was added for 1 h before IGF-I exposure for the indicated times. Cell lysates were immu-
noblotted with an anti-p419Src antibody and reprobed with an anti-Src antibody as a loading control. *P < 0.05 and **P < 0.01 indicate significant
differences between two treatments. The figures are representative of three independent experiments.
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only a 53 6 25% increase after 5 min (P , 0.05) when cells
were maintained in normal glucose (Fig. 3C). The absolute
level of Nox4/p22phox complex formation was reduced by
62 6 1% in cells maintained in normal glucose (P , 0.001).
High glucose alone resulted in a nonsignificant change in
Nox4/p22phox association. Inhibition of either mitogen-
activated protein (MAP) kinase or AKT activation had no
effect on IGF-I–stimulated Nox4/p22phox association (Sup-
plementary Fig. 3C).
Nox4-derived ROS is required for Src oxidation and
activation in response to IGF-I during hyperglycemia.
To definitely determine that Nox4 is the isoform that is
required for Src oxidation and activation, we used Nox4
shRNA. Nox4 expression was reduced ;90% (Fig. 4A), and
silencing Nox4 did not alter the expression of p22phox or
Nox1 (Fig. 4A). Knockdown of Nox4 did not affect IGF-I–
stimulated IGF-I receptor phosphorylation (Supplemen-
tary Fig. 3D). Increasing the glucose concentration from 5
to 25 mmol/L stimulated Nox4 expression in LacZ knock-
down cells by 155 6 17% but it had no effect in cells
expressing Nox4 shRNA (Fig. 4B). High glucose–induced
ROS generation was reduced by 73 6 6% (P , 0.01) in
Nox4 knockdown cells compared with control cells,
whereas the basal ROS level was not significantly different.
This suggests that a Nox4-independent ROS generation
pathway exists (Fig. 4C). Nox4 knockdown prevented IGF-I
stimulation in Src oxidation (e.g., 22 6 9% increase; P =
NS) and activation (e.g., 29 6 9% increase; P = NS),
whereas in control cells, IGF-I induced significant changes
(e.g., 111 6 14%, P , 0.05, and 146 6 12%, P , 0.01, in-
creases, respectively) (Fig. 4D and E). IGF-I–stimulated Src
kinase activity was reduced by 82 6 4% (P , 0.01) com-
pared with control cells exposed to high glucose, whereas
knockdown Nox4 had no effect on IGF-I–stimulated Src
activation when cells were exposed to normal glucose
(Fig. 4F).
High glucose induces Nox4 expression in a PKCz-
dependent manner. To determine the PKC isoform that
mediates the high glucose–induced increase in Nox4 ex-
pression, several PKC inhibitors were used. Only the PKCz
inhibitor prevented the high glucose–induced increase
of Nox4 (Fig. 5A) and IGF-I–stimulated Src activation
(Fig. 5B). To definitively determine if PKCz mediates high
glucose–induced Nox4 expression, we knocked down
PKCz and obtained a 90% reduction (Fig. 5C). Knockdown
of PKCz prevented high glucose–induced Nox4 expression
(Fig. 5D), ROS generation (Supplementary Fig. 4A), and
IGF-I–stimulated Src oxidation (Fig. 5E) and activation
FIG. 3. Hyperglycemia induces Nox4 and p22phox expression, and IGF-I stimulates Nox4/p22phox complex formation during hyperglycemia.
A: VSMCs were cultured in DMEM containing normal glucose (NG; 5 mmol/L) plus 10% FBS and serum deprived for 16 h before adding the in-
dicated concentration of glucose. Mannitol (25 mmol/L) was used as an osmotic control. Cell lysates were immunoblotted with anti-Nox4 (1:500)
and p22phox (1:1,000) antibodies. To control for loading, the blot was stripped and reprobed with an anti–b-actin (1:1,000) antibody. The value of
each bar is the ratio of the scan value of Nox4 or p22phox divided by the value of b-actin, respectively. B and C: Cells were cultured in DMEM
containing high glucose (HG; 25 mmol/L) or NG plus 10% FBS and serum deprived for 16 h before IGF-I treatment for the indicated times (B), or
they were changed to 25 mmol/L glucose (NHG) or maintained in NG for 24 h in the presence or absence of IGF-I for the indicated times (C). Cell
lysates were immunoprecipitated with an anti-p22phox antibody and immunoblotted with an anti-Nox4 antibody. To control loading, the blots were
stripped and probed with an anti-p22phox antibody. The value of each bar is the ratio of the scan value of Nox4 divided by the value of p22phox. *P<
0.05 and ***P < 0.001 indicate significant differences between two treatments. The figures are representative of three independent experiments
except C, which is representative of four.
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(Fig. 5F). IGF-I stimulation of MAP kinase and AKT activa-
tion was also impaired (Supplementary Fig. 4B). Importantly,
the nuclear factor kB (NF-kB) inhibitor (BAY 11–7082) was
able to prevent high glucose–induced Nox4 expression
(Fig. 5G), suggesting that NF-kB is a transcription factor
that mediates PKCz induction of Nox4 expression during
hyperglycemia.
Src oxidation and activation are required for mediating
IGF-I downstream signaling and biological actions. In
VSMCs, Src phosphorylates p52shc, which leads to MAP
kinase activation (31). When VSMCs were exposed to NAC,
IGF-I–stimulated p52shc tyrosine phosphorylation was at-
tenuated (Fig. 6A). Because the IGF-I receptor phosphor-
ylates Src homology 2 domain-containing protein tyrosine
phosphatase substrate-1 (SHPS-1), a transmembrane scaf-
folding protein, and this is required for IGF-I–stimulated
downstream signaling during hyperglycemia, we exam-
ined the effect of NAC on SHPS-1 phosphorylation. IGF-I–
stimulated SHPS-1 tyrosine phosphorylation in the cells
exposed to high glucose was not affected by NAC (Sup-
plementary Fig. 4C), thus excluding the possibility that
NAC functions as a general tyrosine kinase inhibitor. NAC
preincubation also inhibited IGF-I–stimulated MAP ki-
nase and AKT activation (Fig. 6B and C), and this led to
attenuated IGF-I–stimulated cell proliferation (Fig. 6D).
To confirm that the Nox4-mediated increase in ROS was
required, cells expressing Nox4 shRNA were analyzed.
IGF-I–stimulated MAP kinase and AKT activation were
FIG. 4. Knockdown Nox4 prevents hyperglycemia-induced Nox4-
derived ROS generation and IGF-I–stimulated Src oxidation and
activation. VSMCs expressing shRNA targeting LacZ (LacZ Si) and
Nox4 (Nox4 Si) were cultured in DMEM containing high glucose
(HG; 25 mmol/L). A: Cell lysates were immunoblotted with anti-Nox4,
p22phox, Nox1(1:500), and b-actin antibodies. B, D, E and F: Cells
were cultured in the DMEM containing normal glucose (NG; 5 mmol/L),
serum deprived for 16 h, and then changed from NG to HG (NHG;
25 mmol/L) or maintained in NG and incubated for 24 h before IGF-I
exposure. B: Cell lysates were immunoblotted with anti-Nox4 and b-
actin antibodies. C: Cells were cultured in DMEM containing NG or HG
and serum deprived for 16 before measuring ROS levels. ROS measure-
ment was determined according to the procedure described in RESEARCH
DESIGN AND METHODS. D: Src was immunoprecipitated with an anti-Src an-
tibody, and protein oxidation level was measured according to the pro-
cedure described in RESEARCH DESIGN AND METHODS. To control for loading,
the blot was stripped and reprobed with an anti-Src antibody. E: Cell
lysates were immunoblotted with an anti-p419Src antibody and repro-
bed with an anti-Src antibody as a loading control. F: Cell lysates were
immunoprecipitated with an anti-Src antibody before measuring the in
vitro kinase activity according to the procedure described in RESEARCH
DESIGN AND METHODS. *P < 0.05, **P < 0.01, and ***P < 0.001 indicate
significant differences between two cell types or treatments. The fig-
ures are representative of three independent experiments.
FIG. 5. PKCz mediates high glucose (HG)–induced Nox4 expression.
VSMCs or VSMCs expressing shRNA targeting LacZ (LacZ Si) and PKCz
(PKCz Si) were cultured in DMEM containing HG (25 mmol/L) or normal
glucose (NG; 5 mmol/L) plus 10% FBS and serum deprived for 16 h be-
fore changing to HG (25 mmol/L, NHG) or maintained in NG for 24 h.
A: Before lysis, three different PKC inhibitors, PKCz inhibitor (PKCzeta
i; 10 mmol/L), PKC« inhibitor (PKCepsilon i; 20 mmol/L), and conven-
tional PKC inhibitor (cPKC i; 1 mmol/L), were incubated for 2 h. Cell
lysates were immunoblotted with an anti-Nox4 antibody. To control for
loading, the blot was stripped and probed with an anti–b-actin antibody.
B: Before cell lysis, a PKCz inhibitor (10 mmol/L) was added for 2 h. Cell
lysates were immunoblotted with anti-p419Src and anti-Src antibodies.
C: Cell lysates obtained from cultures maintained in HG (25 mmol/L)
were immunoblotted with anti-PKCz (1:1,000) and b-actin antibodies.
D: Cell lysates obtained from cultures maintained in NG or changed from
NG to HG (NHG) were immunoblotted with anti-Nox4 and b-actin anti-
bodies. E: Cell lysates prepared from cultures maintained in HG were
immunoprecipitated with an anti-Src antibody, and protein oxidation
level was measured according to the procedure described in RESEARCH
DESIGN AND METHODS. F: Cell lysates prepared from cultures maintained in
HG were immunoblotted with anti-p419Src and Src antibodies. IGF-I
(100 ng/mL) was added as indicated. G: Different amounts of NF-kB in-
hibitor, as indicated, were preincubated for 1 h before changing glucose.
Cell lysates were immunoblotted with anti-Nox4 and b-actin antibodies.
The figures are representative of three independent experiments.
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impaired (Fig. 6E and F), and this resulted in attenuated
cell proliferation (e.g., 34 6 5% increase vs. 99 6 9%
increase; P , 0.001) (Fig. 6G) and migration (e.g., 45 6 7%
increase vs. 116 6 4% increase; P , 0.001) (Fig. 6H) in re-
sponse to IGF-I.
Hyperglycemia enhances IGF-I–stimulated Src oxidation
and activation, which is prevented by PKCz inhibition
in diabetic mice. To verify that IGF-I stimulated Src oxi-
dation and activation during hyperglycemia in vivo, dia-
betic mice were used. Serum glucose was increased (e.g.,
331 6 20 mg/dL; n = 24) in diabetic mice compared with
normal mice (144 6 9 mg/dL; n = 12). Nox4 and p22phox
were increased in diabetic mice (Fig. 7A), whereas Nox1
expression was unchanged (Supplementary Fig. 4D). The
PKCz inhibitor decreased Nox4 in diabetic mice (Fig. 7A).
Basal Src oxidation was increased 42 6 12% in diabetic
mice compared with normal mice (P , 0.05). IGF-I
induced a further 1386 18% increase in diabetic mice (P,
0.01) whereas it had no effect in normal mice (Fig. 7B).
The absolute Src oxidation level induced by IGF-I was
167 6 34% greater in diabetic mice than normal mice (P ,
0.01). The PKCz inhibitor prevented the IGF-I–induced
increase in Src oxidation in diabetic mice (e.g., 35 6 21%,
P = NS, vs. 138 6 18%, P, 0.01) but had no effect on basal
Src oxidation (Fig. 7B). Basal Src activation was increased
50 6 14% in diabetic mice compared with normal mice
(P , 0.05) but the absolute level of Src activation induced
by IGF-I was increased 1006 29% (P, 0.01) (Fig. 7C). The
PKCz inhibitor inhibited this increase in response to IGF-I.
A similar result was obtained when MAP kinase activation
was determined (Fig. 7D). IGF-I significantly stimulated
Nox4/p22phox complex formation in aorta from diabetic
mice compared with the response of normal mice (e.g.,
81 6 9% increase vs. 23 6 14% increase; P , 0.01), and the
FIG. 6. Prevention of ROS generation impairs IGF-I signal transduction and biological actions. VSMCs were cultured in DMEM containing normal
glucose (NG; 5 mmol/L) or high glucose (HG; 25 mmol/L) plus 10% FBS and serum deprived for 16 h before IGF-I treatment for the indicated times.
For NAC treatment, 2 mmol/L NAC was added in serum-free DMEM and incubated for 16 h. A: Cell lysates were immunoprecipitated with an anti-PY99
antibody followed by immunoblotting with an anti-Shc (1:1,000) antibody. To control loading, the same amount of lysate protein was separated and
immunoblotted using an anti-Shc antibody. B and C: Cell lysates were immunoblotted with anti-pErk1/2 (1:1,000) or pAKT(Ser473) (1:1,000)
antibodies, respectively. To control for loading, the blots were stripped and probed with anti-Erk1/2 (1:1,000) or AKT (1:1,000) antibodies, re-
spectively. D: VSMC proliferation was determined according to a procedure described in RESEARCH DESIGN AND METHODS. E and F: VSMCs expressing
shRNA targeting LacZ (LacZ Si) or Nox4 (Nox4 Si) were cultured in DMEM containing HG plus 10% FBS and serum deprived for 16 h before IGF-I
treatment for the indicated times. Cell lysates were immunoblotted with anti-pErk1/2 or pAKT(Ser473) antibodies, respectively. To control for
loading, the blots were stripped and probed with anti-Erk1/2 or AKT antibodies, respectively. G and H: Cell proliferation and migration were de-
termined as described in RESEARCH DESIGN AND METHODS. **P < 0.01 and ***P < 0.001 indicate significant differences between two cell types or
treatments. The figures are representative of three independent experiments.
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absolute level induced by IGF-I was 77 6 20% greater than
in normal mice (P , 0.05) (Fig. 7E). The PKCz inhibitor
prevented the effect of IGF-I in diabetic mice (e.g., 17 6 4
vs. 81 6 9% increase; P , 0.01). The diabetic mice had a
19 6 6% increase in complex formation compared with
nondiabetic mice (P, 0.05). To examine an IGF-I–stimulated
biological action, Ki67 labeling (an indicator of cell pro-
liferation) was analyzed. Hyperglycemia alone increased
Ki67 labeling compared with normal mice (e.g., 57 6 18%
increase; P , 0.05). IGF-I stimulated a major increase in
diabetic mice (e.g., 1896 32% increase; P, 0.01) but it had
no significant effect in the normal mice. The PKCz in-
hibitor prevented the IGF-I–stimulated increase in diabetic
mice, suggesting that PKCz activity is required for in-
creased VSMC replication in vivo (Fig. 8).
DISCUSSION
In VSMCs exposed to hyperglycemia, IGF-I stimulates Src
activation, and this is required for MAP kinase and AKT
FIG. 7. Hyperglycemia enhances IGF-I–stimulated oxidation and activation of Src, which is prevented by a PKCz inhibitor in vivo. The 8–10-week-
old male C57/B6 mice were injected with streptozotocin (50 mg/kg i.p., diluted in citrate buffer; diabetic mice [DM]; n = 24) or with citrate buffer
(normal mice [NM]; n = 12) for 5 consecutive days. The DM and NM were maintained for 2 weeks before analysis. Before they were killed, half of
DM (n = 12) were injected daily with a PKCz inhibitor (PKCzeta i; 2 mg/kg) for 2 days. In addition, half of normal (n = 6) or diabetic (n = 12) mice
were injected with IGF-I (1 mg/kg body weight i.p., diluted in PBS) or PBS alone (control) for 15 min before they were killed by injection of
Nembutal (100 mg/kg i.p.). Aortic extracts were prepared using the procedure described in RESEARCH DESIGN AND METHODS. A: Aortic extracts were
immunoblotted using anti-Nox4, p22phox, and b-actin antibodies. B: The Src protein oxidation level was measured according to a procedure
described in RESEARCHDESIGN ANDMETHODS. C: Aortic extracts were immunoblotted using an anti-p419Src antibody. The blot was stripped and probed
with anti-Src antibody as a loading control. D: Aortic extracts were immunoblotted using an anti-pErk1/2 antibody. The blot was stripped and
probed with anti-Erk1/2 antibody as a loading control. E: Aortic extracts were immunoprecipitated using an anti-p22phox antibody and immu-
noblotted using an anti-Nox4 antibody. The blot was stripped and probed with an anti-p22phox antibody as a loading control. The value of each bar
is either the ratio of the scan value of oxidized Src divided by the value of Src (B), the ratio of the scan value of p419Src divided by the value of Src
(C), or the ratio of the scan value of Nox4 divided by the value of p22phox (E). *P < 0.05 and **P < 0.01 indicate significant differences between
two treatments or the two types of mice. The figures are representative of four independent experiments.
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activation (6,24). In the current study, we demonstrate that
Src kinase activation requires the induction of a specific
NAPDH oxidase, Nox4. Exposure of VSMCs to high glu-
cose significantly increased expression of both Nox4 and
p22phox, and PKCz mediated the increase of Nox4. After
exposure to hyperglycemia, the role of IGF-I appears to be
to stimulate Nox4/p22phox complex formation, which is
required for optimal ROS generation and Src activation.
Reduction in Nox4 expression decreased Src oxidation,
and this resulted in the loss of IGF-I–stimulated Src acti-
vation as well as attenuated cell proliferation and migration.
Previous studies have shown that Src kinase can be
activated by multiple stimuli, such as angiotensin-II (14)
and IGF-I (6). This study focused on the mechanism by
which IGF-I stimulated Src activation during hyperglyce-
mia and the role of Nox4-derived ROS. Crystal structure
data show that disruption of intramolecular interactions in
Src allows Y419 to be more accessible and thus fully ac-
tivated (10). However, it is not clear what allows these
domains to be become more accessible when Src is in the
folded (inactive) conformation. That redox regulation may
be involved is supported by studies that show that Src is
activated by oxidation of cysteines and that this effect is
reversible (32). One study implicated Nox4-derived ROS
in angiotensin II–stimulated Src oxidation and activation
(14). The proposed mechanism was that after oxidation, an
intramolecular bond formed between two cysteines, which
favored maintaining Src in the open conformation (15). In
support of this hypothesis, a recent study revealed that
oxidation of two neighboring cysteines leads to a confor-
mational change in the SH3 domain, which alters the helix-
sheet packing (33). Our results show that the increase in
ROS induced by hyperglycemia leads to increased Src
oxidation and that IGF-I stimulated a further increase in
VSMCs and in diabetic mice. That Src oxidation is pre-
requisite for Src activation is supported by the observations
that NAC prevented and H2O2 stimulated Src oxidation and
Src kinase activation in response to IGF-I. Even though high
glucose alone was sufficient to induce a major increase in
Src oxidation, activation of Src in VSMCs also required
stimulation by IGF-I. Because previous studies had shown
that high glucose alone could activate Src (34,35), we ex-
amined the time course of Src activation. The results
showed that high glucose–induced Src kinase activation
lasted a short period of time (e.g., 10 min to 1 h) and that it
subsequently returned to a basal level (Supplementary Fig.
4H). The increase Src oxidation induced by high glucose
alone significantly exceeded Src activation after 14 h and
at later time points. Furthermore, at time points later than
1 hour, IGF-I was required to induce a significant increase
in Src activation. Our in vivo results also showed that
optimal Src activation could only be obtained in IGF-I–
treated diabetic mice. Because IGF-I induced a signifi-
cantly greater increase in Src oxidation compared with
glucose alone, it is possible that a high level of Src oxi-
dation is required for its sustained activation. Alternatively,
because the increased Nox4/p22phox association was im-
portant, it is possible that they colocalize with Src at
a distinct location and that this localized increase in Src
oxidation is required. We previously reported that Src (6)
and Nox4 (36) are recruited to phosphorylated scaffold
protein, SHPS-1, and that IGF-I receptor phosphorylation
of SHPS-1 mediates this recruitment. Therefore this mech-
anism could account for the requirement for IGF-I to
stimulate optimal Src activation. It is also possible that
Src interacts with other binding partners, which allow
oxidation of cysteines, such as Cys487, thus permitting Src
activation (13).
Among the Nox isoforms, Nox4 and Nox1 are two major
isoforms in vascular cells (19) and are a major source of
intracellular ROS (18). However, the expression of Nox4 is
abundant whereas Nox1 expression is relatively low in
vascular cells (37). Consistently, we detected only a slight
increase of Nox1 in VSMCs exposed to high glucose in
vitro and no change in diabetic mice. More importantly,
knockdown Nox1 in VSMCs exposed to high glucose did
not affect IGF-I–stimulated Src oxidation and activation
(Supplementary Fig. 4E–G). Therefore, we focused on
Nox4-derived ROS. To generate ROS, Nox4 associates with
p22phox (38). High glucose has been shown to increase
both Nox4 and p22phox expression in endothelial cells
(37,39), and our study clearly shows that high glucose
significantly increased both Nox4 and p22phox expression
in VSMCs. Because the change of Nox4 requires increased
transcription, the induction in Nox4 by high glucose was
delayed but it persisted for at least 24 h, and this is a key
requirement for IGF-I to be able to stimulate a major in-
crease in Nox4/p22phox complex formation.
IGF-I stimulated Nox4/p22phox complex formation in
VSMCs exposed to high glucose and in diabetic mice. Be-
cause Nox4/p22phox complex formation is required for
Nox4-derived ROS (38), this change appears to account for
a significant part of the change in Src activation that oc-
curred in response to IGF-I. By contrast, a recent study,
that did not analyze the effect of glucose, showed that
increased Nox4 expression accounted for IGF-I–induced
ROS generation in rat VSMCs (20). However, in that study,
increased ROS was detected after 5 min of IGF-I treatment
whereas the increase of Nox4 expression required a 4-h
exposure to IGF-I. Our results show that a short time ex-
posure to IGF-I had a minimal effect on Src oxidation,
Nox4 induction, p22phox/Nox4 association, or Src Y419
phosphorylation in cells maintained in 5 mmol/L glucose,
and significant increases required exposure to high glu-
cose. Therefore, the increase in Nox4 expression induced
by high glucose appears to be required for IGF-I to stim-
ulate a major increase in Nox4/p22phox complex formation.
The requirement for Nox4-derived ROS for IGF-I–stimulated
Src oxidation and activation was reinforced by our results
obtained after Nox4 silencing. They showed that sup-
pression of Nox4 significantly attenuated high glucose–
induced ROS generation as well as IGF-I–stimulated Src
oxidation and activation.
Previous studies have shown that different isoforms of
PKC mediate high glucose–induced Nox4 expression in vivo
(40) and in vitro (21,41). Utilizing specific PKC isoform
inhibitors and silencing, our data show that PKCz is re-
sponsible for the high glucose–induced Nox4 upregulation,
Src oxidation, and activation in both VSMCs and diabetic
mice. IGF-I–stimulated Nox4/p22phox complex formation
was prevented when a PKCz inhibitor was administrated in
the diabetic mice. Because PKCz has been shown to me-
diate NF-kB pathway activation (42,43), and NF-kB has
been shown to mediate tumor necrosis factor-a (30) and
hypoxia-induced (44) Nox4 expression in SMC, we postu-
lated that PKCz mediates high glucose–induced Nox4 ex-
pression via activation of the NF-kB pathway. In support of
this hypothesis, our data show that an NF-kB inhibitor
prevented high glucose–induced Nox4 expression.
The interaction between ROS and growth factor signal
transduction has been previously reported. H2O2 generation
is essential for mediating platelet-derived growth factor
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signal transduction in VSMCs (45) and epidermal growth
factor signaling in epithelial cells (46). The mechanism that
was proposed initially was that H2O2 inhibited the activa-
tion of tyrosine phosphatases, including protein tyrosine
phosphatase 1B and SHP-2, which altered the balance be-
tween kinase and phosphatase activity and resulted in en-
hanced actions. Recent studies have indicated that
increased ROS leads to Src oxidation, and activated Src
directly phosphorylates epidermal growth factor receptor
on tyrosine 845 (47). Our results demonstrate that genera-
tion of ROS is required for mediating IGF-I–stimulated Src
activation as well as downstream signaling and biological
actions. Although our in vivo data indicated that hypergly-
cemia alone was able to induce an increase in cell pro-
liferation in vivo, this is not surprising because these cells
secrete growth factors, such as TGF-b, and they are exposed
to plasma, which contains several mitogens, including IGF-I.
However, a more robust proliferative response was detected
after IGF-I treatment in diabetic mice, and the PKCz in-
hibitor prevented this response. These results strongly
support the conclusion that enhanced ROS generation
and Src oxidation in response to hyperglycemia play vital
roles in mediating the VSMC proliferative response to
IGF-I. These findings are relevant to diabetic patients who
are receiving insulin because insulin has been shown to in-
crease serum IGF-I concentrations in diabetic patients (48)
and diabetic animals (49).
In summary, our study provides direct evidence for IGF-I–
stimulated Src oxidation during hyperglycemia, which is
required for Src activation in response to IGF-I in VSMCs.
Hyperglycemia induces Nox4 and p22phox expression, and
IGF-I induces Nox4 and p22phox complex formation, lead-
ing to increased ROS generation and Src activation. High
glucose induces Nox4 upregulation in a PKCz/NF-kB–
dependent manner. Disruption of ROS generation via either
knockdown of Nox4 or PKCz or preincubation with NAC
impairs Src oxidation and activation in response to IGF-I,
and this leads to impaired IGF-I signal transduction and
biological actions. This study defines the molecular events
that lead to hyperglycemia/IGF-I–stimulated ROS generation
and Src activation in VSMCs and blood vessels of diabetic
mice, and provides a framework for developing methods to
modify the vascular response to hyperglycemic stress.
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